Eli Lilly and Company (LLY)

Over the past six months, Eli Lilly's stock has experienced significant activity, increasing by 32.50% from April 10, 2025, to April 9, 2026. As of April 10, 2026, the closing share price was $939.47. Key events impacting the stock include Eli Lilly reaching a $1 trillion market capitalization in November 2025, Mounjaro and Zepbound generating $10.1 billion in combined revenue in Q3 2025, and Eli Lilly reporting $7.54 earnings per share (EPS) in Q4 2025. The FDA approval of Foundayo also boosted growth prospects, and several research firms updated their price targets and ratings. Reports in April 2026 indicated that Lilly's market share was dipping amid an intensifying weight-loss drug market, and Centessa Pharma is to be acquired by Eli Lilly for $8 billion. Eli Lilly is expected to release its Q1 2026 earnings on April 30, 2026.

While specific details on demand seasonality for Eli Lilly & Co.'s products and services are not extensively detailed, the stock itself exhibits some seasonal trends. For example, April has historically shown a chance of being a "green month" for LLY, with 58% of previous Aprils closing higher than March over 49 years.

Eli Lilly and Company is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, operating within the pharmaceutical sector. It focuses on the discovery, development, manufacturing, and sale of human pharmaceutical products across key therapeutic areas, including cardiometabolic health, oncology, immunology, and neuroscience. Major products include Tirzepatide (Mounjaro and Zepbound), Abemaciclib (Verzenio), Dulaglutide (Trulicity), Ixekizumab (Taltz), Empagliflozin (Jardiance), Insulin lispro (Humalog), Ramucirumab (Cyramza), Baricitinib (Olumiant), Insulin (Humulin), Galcanezumab (Emgality), and Kisubla, along with other products like Basaglar and various Humalog and Humulin formulations.

Eli Lilly and Co. is a multinational company with offices in 18 countries and products sold in approximately 125 countries. The company operates an extensive network of 402 subsidiaries across the world, with the largest number in the United States (188 subsidiaries), followed by India (25 subsidiaries) and China (24 subsidiaries). The United States is the largest region for Eli Lilly, representing 67.44% of its total revenue in fiscal year 2025, while China represents the smallest at 3.69%. The company also has a significant presence in Europe, with over 9,000 employees and R&D and manufacturing sites in countries such as Spain, France, Ireland, Italy, and Germany. Eli Lilly is expanding its manufacturing footprint globally, with significant investments in facilities in Europe (the Netherlands) and India, in addition to its US operations.

In the past year, Eli Lilly's brand reputation has been significantly bolstered by the success of its GLP-1 medications, Mounjaro and Zepbound, for diabetes and obesity. The company's brand value surged by 53% in 2024, reaching nearly $6 billion. However, pricing and generic pressure in India and a market share dip in the weight-loss drug market could potentially affect its reputation.

Eli Lilly & Co.'s ownership structure is a mix of institutional, retail, and individual investors. Institutional investors hold approximately 41.50% of the company's stock, while insiders own about 9.88%, and public companies and individual investors hold 48.62%. Lilly Endowment Inc. is the largest shareholder, followed by Vanguard Group Inc., BlackRock, Inc., PNC Financial Services Group, Inc., State Street Corp, FMR LLC, Capital Research Global Investors, Geode Capital Management, LLC, and Morgan Stanley.